Senti Biosciences, Inc. (NASDAQ:SNTI) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Senti Biosciences, Inc. (NASDAQ:SNTI) have earned a consensus rating of “Moderate Buy” from the five research firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $9.00.

A number of equities analysts recently issued reports on the stock. Wall Street Zen raised shares of Senti Biosciences to a “sell” rating in a report on Saturday, December 13th. Leerink Partners started coverage on shares of Senti Biosciences in a research note on Friday, November 21st. They set an “outperform” rating and a $6.00 price target on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Senti Biosciences in a research note on Thursday, January 22nd. Finally, Chardan Capital lifted their target price on Senti Biosciences from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th.

Institutional Investors Weigh In On Senti Biosciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Armistice Capital LLC bought a new stake in Senti Biosciences during the 2nd quarter worth approximately $1,883,000. Geode Capital Management LLC raised its position in shares of Senti Biosciences by 395.6% during the 2nd quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock valued at $311,000 after purchasing an additional 117,588 shares during the period. Citadel Advisors LLC purchased a new position in shares of Senti Biosciences during the 3rd quarter valued at $117,000. Virtu Financial LLC bought a new position in Senti Biosciences in the 4th quarter worth $46,000. Finally, Jane Street Group LLC purchased a new stake in Senti Biosciences in the 4th quarter worth $40,000. 25.70% of the stock is owned by hedge funds and other institutional investors.

Senti Biosciences Stock Performance

Shares of NASDAQ:SNTI opened at $0.94 on Friday. The stock’s 50-day simple moving average is $1.01 and its two-hundred day simple moving average is $1.46. The stock has a market capitalization of $24.82 million, a price-to-earnings ratio of -0.28 and a beta of 2.13. Senti Biosciences has a 52-week low of $0.80 and a 52-week high of $5.10.

Senti Biosciences Company Profile

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.